Il y a eu 50 transactions d'initiés récentes enregistrées pour IDEAYA Biosciences, Inc. (IDYA), dont 37 achats et 10 ventes. Le total des achats d'initiés s'élève à $128.94M et le total des ventes d'initiés à $1.89M.
Les initiés notables ayant une activité récente comprennent Stein Jeffrey, Beaupre Darrin, Hata Yujiro S. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.
Transactions d'Initiés — IDYA
| Date |
Nom |
Rôle |
Type de Transaction |
Actions |
Prix Moyen |
Valeur |
Actions détenues |
| 2026-03-02 |
Stein Jeffrey |
Director |
Achat Informatif |
50,000 |
$32.96 |
$1.65M |
54,281 |
| 2026-01-30 |
Beaupre Darrin |
Chief Medical Officer |
Attribution de RSU |
175,000 |
$32.19 |
$5.63M |
175,000 |
| 2026-01-30 |
Hata Yujiro S |
President and CEO |
Attribution de RSU |
600,000 |
$32.19 |
$19.31M |
600,000 |
| 2026-01-30 |
Snyder Douglas B. |
SVP, General Counsel |
Attribution de RSU |
130,000 |
$32.19 |
$4.18M |
130,000 |
| 2026-01-30 |
White Michael Anthony |
Chief Scientific Officer |
Attribution de RSU |
190,000 |
$32.19 |
$6.12M |
190,000 |
| 2026-01-30 |
Ruiz Briseno Andres |
See Remarks |
Attribution de RSU |
80,000 |
$32.19 |
$2.58M |
80,000 |
| 2026-01-30 |
Dorman Stuart |
Chief Commercial Officer |
Attribution de RSU |
155,000 |
$32.19 |
$4.99M |
155,000 |
| 2026-01-30 |
Bleharski Joshua |
Chief Financial Officer |
Attribution de RSU |
170,000 |
$32.19 |
$5.47M |
170,000 |
| 2025-11-28 |
Snyder Douglas B. |
SVP, General Counsel |
Attribution de RSU |
1,041 |
$16.91 |
$17.6K |
2,080 |
| 2025-11-28 |
Ruiz Briseno Andres |
See Remarks |
Attribution de RSU |
1,253 |
$16.91 |
$21.18K |
26,466 |
| 2025-06-27 |
Bleharski Joshua |
Chief Financial Officer |
Inconnu |
250,000 |
$20.05 |
$5.01M |
- |
| 2025-06-24 |
Yarno Wendy L |
Director |
Attribution de RSU |
20,000 |
$21.78 |
$435.6K |
20,000 |
| 2025-06-24 |
Rosen Terry J |
Director |
Attribution de RSU |
20,000 |
$21.78 |
$435.6K |
20,000 |
| 2025-06-24 |
Stein Jeffrey |
Director |
Attribution de RSU |
20,000 |
$21.78 |
$435.6K |
20,000 |
| 2025-06-24 |
Mackey Catherine J |
Director |
Attribution de RSU |
20,000 |
$21.78 |
$435.6K |
20,000 |
| 2025-06-24 |
Morrison Scott W |
Director |
Attribution de RSU |
20,000 |
$21.78 |
$435.6K |
20,000 |
| 2025-06-24 |
Hampton Malcolm Garret |
Director |
Attribution de RSU |
20,000 |
$21.78 |
$435.6K |
20,000 |
| 2025-05-30 |
Snyder Douglas B. |
SVP, General Counsel |
Attribution de RSU |
1,039 |
$16.91 |
$17.57K |
1,039 |
| 2025-02-27 |
Beaupre Darrin |
Chief Medical Officer |
Attribution de RSU |
185,000 |
$20.24 |
$3.74M |
185,000 |
| 2025-02-27 |
Hata Yujiro S |
President and CEO |
Attribution de RSU |
600,000 |
$20.24 |
$12.14M |
600,000 |
| 2025-02-27 |
Snyder Douglas B. |
SVP, General Counsel |
Attribution de RSU |
33,000 |
$20.24 |
$667.92K |
33,000 |
| 2025-02-27 |
White Michael Anthony |
Chief Scientific Officer |
Attribution de RSU |
185,000 |
$20.24 |
$3.74M |
185,000 |
| 2025-02-27 |
Ruiz Briseno Andres |
See Remarks |
Attribution de RSU |
75,000 |
$20.24 |
$1.52M |
75,000 |
| 2025-02-27 |
Dorman Stuart |
Chief Commercial Officer |
Attribution de RSU |
15,000 |
$20.24 |
$303.6K |
15,000 |
| 2025-02-18 |
Hata Yujiro S |
President and CEO |
Exercice d'Options (Vente) |
12,808 |
$19.52 |
$250.01K |
182,192 |
| 2024-12-11 |
Dorman Stuart |
Chief Commercial Officer |
Inconnu |
170,000 |
$27.45 |
$4.67M |
- |
| 2024-11-29 |
Ruiz Briseno Andres |
See Remarks |
Attribution de RSU |
682 |
$23.26 |
$15.86K |
25,213 |
| 2024-09-26 |
Snyder Douglas B. |
SVP, General Counsel |
Attribution de RSU |
140,000 |
$30.50 |
$4.27M |
140,000 |
| 2024-09-18 |
Snyder Douglas B. |
Officer |
Inconnu |
- |
- |
- |
- |
| 2024-06-27 |
Throne Jason |
Chief Legal Officer |
Exercice d'Options (Vente) |
47,060 |
$7.01 |
$329.89K |
1,360 |
| 2024-05-31 |
Yarno Wendy L |
Director |
Attribution de RSU |
16,200 |
$36.55 |
$592.11K |
16,200 |
| 2024-05-31 |
Rosen Terry J |
Director |
Attribution de RSU |
16,200 |
$36.55 |
$592.11K |
16,200 |
| 2024-05-31 |
Stein Jeffrey |
Director |
Attribution de RSU |
16,200 |
$36.55 |
$592.11K |
16,200 |
| 2024-05-31 |
Kelley Susan L. |
Director |
Attribution de RSU |
16,200 |
$36.55 |
$592.11K |
16,200 |
| 2024-05-31 |
Mackey Catherine J |
Director |
Attribution de RSU |
16,200 |
$36.55 |
$592.11K |
16,200 |
| 2024-05-31 |
Morrison Scott W |
Director |
Attribution de RSU |
16,200 |
$36.55 |
$592.11K |
16,200 |
| 2024-05-31 |
Hampton Malcolm Garret |
Director |
Attribution de RSU |
16,200 |
$36.55 |
$592.11K |
16,200 |
| 2024-05-29 |
White Michael Anthony |
Chief Scientific Officer |
Vente Informative |
851 |
$36.78 |
$31.3K |
- |
| 2024-05-16 |
Hata Yujiro S |
President and CEO |
Exercice d'Options (Vente) |
34,433 |
$4.31 |
$148.41K |
49,454 |
| 2024-05-15 |
Hata Yujiro S |
President and CEO |
Exercice d'Options (Vente) |
83,856 |
$4.31 |
$361.42K |
83,887 |
| 2024-05-14 |
Hata Yujiro S |
President and CEO |
Exercice d'Options (Vente) |
56,711 |
$4.31 |
$244.42K |
167,743 |
| 2024-03-01 |
Beaupre Darrin |
Chief Medical Officer |
Attribution de RSU |
160,000 |
$46.22 |
$7.4M |
160,000 |
| 2024-03-01 |
Hata Yujiro S |
President and CEO |
Attribution de RSU |
480,000 |
$46.22 |
$22.19M |
480,000 |
| 2024-03-01 |
Throne Jason |
Chief Legal Officer |
Attribution de RSU |
125,500 |
$46.22 |
$5.8M |
125,500 |
| 2024-03-01 |
White Michael Anthony |
Chief Scientific Officer |
Attribution de RSU |
140,000 |
$46.22 |
$6.47M |
140,000 |
| 2024-03-01 |
Ruiz Briseno Andres |
See Remarks |
Attribution de RSU |
85,000 |
$46.22 |
$3.93M |
85,000 |
| 2024-02-09 |
Hata Yujiro S |
President and CEO |
Exercice d'Options (Vente) |
23,557 |
$4.31 |
$101.53K |
224,454 |
| 2024-02-09 |
Ruiz Briseno Andres |
See Remarks |
Vente Informative |
2,000 |
$46.02 |
$92.04K |
24,531 |
| 2024-02-08 |
Hata Yujiro S |
President and CEO |
Exercice d'Options (Vente) |
75,815 |
$4.31 |
$326.76K |
248,011 |
| 2024-02-01 |
Hata Yujiro S |
President and CEO |
Exercice d'Options (Vente) |
628 |
$4.31 |
$2.71K |
323,826 |
■ Informatif — transaction sur marché ouvert (la plus significative)
■ Non informatif (achat) — récompense, exercice d'option, conversion
■ Non informatif (vente) — retenue fiscale, vente à l'acquisition
■ Neutre — don, fiducie, expiration
Les autres consultent aussi
